[Surfactant therapy in newborns with hyaline membrane disease].
Tsvetkova
S
S
Chernookova
V
V
Efremova
R
R
Nedeva
N
N
Bogdanova
V
V
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000627:therapeutic use*; D005865:Gestational Age; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy*; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D019102:Infant, Very Low Birth Weight; D007385:Intermittent Positive-Pressure Ventilation / Q000379:methods*; D010102:Oxygen Inhalation Therapy / Q000379:methods*; D010743:Phospholipids; D010767:Phosphorylcholine; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012189:Retrospective Studies
D001688:Biological Products; D004338:Drug Combinations; D005233:Fatty Alcohols; D010743:Phospholipids; D011663:Pulmonary Surfactants; D010767:Phosphorylcholine; D011092:Polyethylene Glycols; C047049:dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug combination; C068291:poractant alfa